GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » 5-Year Yield-on-Cost %

Nanomix (Nanomix) 5-Year Yield-on-Cost % : 0.00 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nanomix 5-Year Yield-on-Cost %?

Nanomix's yield on cost for the quarter that ended in Dec. 2022 was 0.00.


The historical rank and industry rank for Nanomix's 5-Year Yield-on-Cost % or its related term are showing as below:



NNMX's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.195
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Nanomix's 5-Year Yield-on-Cost %

For the Medical Devices subindustry, Nanomix's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanomix's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Nanomix's 5-Year Yield-on-Cost % falls into.



Nanomix 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Nanomix is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Nanomix  (OTCPK:NNMX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Nanomix 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Nanomix's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanomix (Nanomix) Business Description

Traded in Other Exchanges
N/A
Address
2121 Williams Street, San Leandro, CA, USA, 94577
Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.
Executives
Chris Hetterly officer: Chief Financial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener director, 10 percent owner ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger director, officer: CEO C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney officer: Chief Operating Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky officer: Chief Commercial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson director, officer: CEO and President BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman director 1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham officer: Chief Operating Officer C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch director, officer: CEO
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng director ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia officer: Chief Financial Officer PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin director C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome officer: Chief Operating Officer (3) 178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz director 33 KACHAL STREET, LEHAVIM L3 85338